Actively Recruiting
Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
Led by Jiangsu HengRui Medicine Co., Ltd. · Updated on 2025-09-10
351
Participants Needed
2
Research Sites
116 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multicenter, phase 2, open label study to evaluate safety, tolerability and efficacy of SHR2554 combined with other anti-tumor treatments in patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
CONDITIONS
Official Title
Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- At least 18 years old or the minimum legal adult age when signing consent
- Has at least one measurable lesion by CT or MRI based on RECIST v1.1 at screening
- Willing to provide an adequate tumor sample
- Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 at screening
You will not qualify if you...
- Difficulty swallowing or other issues preventing oral intake of SHR2554
- Prior treatment with any enhancer of zeste homolog inhibitors
- Uncontrolled or significant cardiovascular disease
- Spinal cord compression or active central nervous system metastases requiring treatment
- Active autoimmune diseases needing systemic corticosteroids or immunosuppressants
- Known allergy to SHR2554 or its ingredients
- Ongoing uncontrolled systemic infections needing intravenous antibiotics, antivirals, or antifungals
- Diagnosis of other cancers within 5 years before starting study treatment
- History or current interstitial lung disease, pneumonitis requiring steroids, or significant lung disease
- Psychological, social, familial, or geographical factors preventing regular follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China, 150081
Actively Recruiting
2
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China, 450052
Actively Recruiting
Research Team
B
Botao Zhu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here